Skip to main content

CRL in the News

The FDA-authorized, saliva-based COVID-19 RT-PCR test expands testing access with a comfortable, at-home alternative – eliminating in-person waits and reducing exposure risk

DEERFIELD, Ill. and LENEXA, Kan.Feb. 24, 2021 /PRNewswire/ — Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care®, a digital health platform available on the Walgreens app and Walgreens.com. Sold under CRL’s HealthConfirm® brand, the COVID-19 Saliva Test is non-invasive and highly accurate, offering consumers the convenience of self-collecting the test right in their homes without supervision.
Read More

Self-Collected CRL Rapid Response™ Saliva Test is More Accurate Than Widely Used Anterior Nasal Swab Test and Key to the U.S. Safely Getting Back to Work
LENEXA, Kan., July 31, 2020 /PRNewswire/ — Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response™, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting. The test, shown in CRL’s EUA studies to be more sensitive and accurate than the standard COVID-19 anterior nasal swab test, detects the presence of coronavirus in the saliva of the test taker. In addition, the test is more comfortable and easier to administer, is not “technique dependent” and virtually anyone can self-collect an adequate sample for testing, with test results available in 24-48 hours of receipt at CRL. CRL Rapid Response™ is ready for immediate commercial launch, making it the first large-scale service of its kind focused on the American workforce. Testing is critical to safely helping America get back to work, which is why CRL is offering these tests to employers in businesses, universities, government agencies, nursing homes and other organizations. CRL has already lined up several partnerships for CRL Rapid Response™ testing.
Read More
Highly Accurate CRL Rapid Response™ Saliva Test is Easy to Use, Competitively Priced; Delivers Results Right to Cell Phone
LENEXA, Kan., Nov. 9, 2020 /PRNewswire/ — Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response™ saliva-based COVID-19 RT-PCR test directly to consumers. At $110 (which includes the cost of prepaid FedEx Priority Overnight shipping in both directions), the easy-to-use, highly accurate test is one of the most affordable COVID-19 home tests currently available in the market and the least expensive at-home saliva test.
Strategic Partners Will Benefit from Complementary Strengths; Confirm BioSciences to Continue Operating Under Its Current Name

SAN DIEGO and LENEXA, Kan., Dec. 9, 2020 /PRNewswire/ — Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, announced today that the company has been acquired by Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S. Confirm will continue to operate as a subsidiary under its current name. The acquisition expands Confirm’s access to lab testing services and R&D capabilities, while CRL leverages Confirm’s massive customer base in Drugs of Abuse testing, large consumer-based retail contracts and current pipeline of COVID-19 testing products.
Read More

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®
Clinical Reference Laboratory’s FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2
As Covid-19 Variants Invade, Testing Remains A Critical Line Of Defense

The pace of vaccine rollout is encouraging, but the war is not over—and companies still have a key role to play in preventing another debilitating surge.
Read More